Intellipharmaceutics International Inc. (IPCIF)の価格はいくらですか

Intellipharmaceutics International Inc. (IPCIF)の価格は$0.15です

Intellipharmaceutics International Inc. (IPCIF)の時価総額は何ですか

Intellipharmaceutics International Inc. (IPCIF)の時価総額は$4.96Mです

Intellipharmaceutics International Inc.（IPCIF）株式分割

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. It also provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. In addition, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.

年	株式分割	分割比率	累積分割比率
2018-09-14	1:10	x0.1	x0.00066
2009-10-22	33:500	x0.066	x0.0066
2007-04-17	1:10	x0.1	x0.1

年

株式分割

分割比率

累積分割比率

2018-09-14

1:10

x0.1

x0.00066

2009-10-22

33:500

x0.066

x0.0066

2007-04-17

1:10

x0.1

企業	株式分割の回数	累積分割比率	国
Novo Nordisk A/S NVO.US	5	x199	DK
Vertex Pharmaceuticals Incorporated VRTX.US	1	x2	US
Regeneron Pharmaceuticals, Inc. REGN.US	0	-	US
UCB SA UCB.BR	0	-	BE
Argenx SE ARGX.US	0	-	NL

企業

株式分割の回数

累積分割比率

国